Sufentanil

Mechanism :

It binds to opioid receptors throughout the CNS and it exerts its effects by opening K+ channels and inhibiting Ca++ channels.

Indication :

• Epidural analgesia
• Surgical analgesia and surgical anaesthesia

Contraindications :

Hypersensitivity to sufentanil or any component of the formulation; epidural administration in patients with severe hemorrhage or shock, septicemia, or infection at proposed puncture site.

Dosing :

Adverse Effect :

Pruritus (on epidural administration), Bradycardia, hypotension, peripheral vasodilation, Drug dependence, Decreased gastrointestinal motility, nausea, vomiting, muscle rigidity, miosis, apnea, respiratory depression.

Interaction :

Blood Pressure Lowering Agents: May enhance the hypotensive effect of Hypotension-Associated Agents.
Bradycardia-Causing Agents: May enhance the bradycardic effect of other Bradycardia-Causing Agents.
CNS Depressants: May enhance the CNS depressant effect of Opioid Analgesics.
CYP3A4 Inducers: May decrease the serum concentration of Sufentanil.
CYP3A4 Inhibitors: May increase the serum concentration of Sufentanil.
Diuretics: Opioid Analgesics may enhance the adverse/toxic effect of Diuretics.
Gastrointestinal Agents (Prokinetic): Opioid Analgesics may diminish the therapeutic effect of Gastrointestinal Agents.
Monoamine Oxidase Inhibitors: Sufentanil may enhance the adverse/toxic effect of Monoamine Oxidase Inhibitors. Specifically, the risk for serotonin syndrome or opioid toxicities may be increased.
Opioid Analgesics: CNS Depressants may enhance the CNS depressant effect of Opioid Analgesics.

Hepatic Dose :